HK:2652 Stock Latest News
Company AnnouncementsCF PharmTech Core Management Voluntarily Extends Share Lock-Up by Six Months2w ago2652
Company AnnouncementsCF PharmTech Advances Inhaled ILD Drug ICF004 With First Dosing in Phase I Trial1M ago2652
Company AnnouncementsCF PharmTech Wins Expanded Trial Approvals for Inhaled Lung Disease Candidate ICF0012M ago2652- Company AnnouncementsCF PharmTech Board to Review Interim Results and Consider Dividend2M ago2652
Company AnnouncementsCF PharmTech completes HK$13.82 H-share placing to broaden investor base2M ago2652
Company AnnouncementsCF PharmTech Launches Discounted HK$300 Million H-Share Placing2M ago2652
Company AnnouncementsCF PharmTech cuts H-share board lot size to boost liquidity4M ago2652
Company AnnouncementsCF PharmTech Wins PIC/S GMP Clearance for Suzhou Inhalation Plant4M ago2652
Company AnnouncementsCF PharmTech Wins NMPA IND Nod for First-in-Class Inhaled Lung Disease Drug4M ago2652
Company AnnouncementsCF PharmTech Reshapes Board and Supervisory Leadership Ahead of AGM4M ago2652Company AnnouncementsCF PharmTech Outlines Board and Committee Structure to Strengthen Governance4M ago2652
Company AnnouncementsCF PharmTech Files for CF017 Marketing Approval in Key Southeast Asian Market5M ago2652
Company AnnouncementsCF PharmTech’s COPD Inhalation Therapy Accepted for NMPA Review5M ago2652
Company AnnouncementsCF PharmTech Endures Transitional Year as Revenue Falls Amid Strategy Shift7M ago2652- Company AnnouncementsCF PharmTech Taps JD Health as Exclusive Online Partner for New Respiratory Drugs7M ago2652
- Company AnnouncementsCF PharmTech Issues Profit Warning as VBP Pressure Hits 2025 Earnings7M ago2652
Company AnnouncementsCF PharmTech Sets Board Meeting to Approve 2025 Annual Results and Consider Final Dividend7M ago2652Company AnnouncementsCF PharmTech Wins NMPA IND Acceptance for Novel Inhaled Pulmonary Hypertension Drug7M ago2652
Company AnnouncementsCF PharmTech Wins NMPA Nod for Clinical Trials of New Combination Nasal Spray7M ago2652